DrugAnalyst Consensus Database

DRUGANALYST LTD
172 TOTTENHAM COURT RD
LONDON W1T 7NS
+44 20 3696 7500
This is a guest preview - full consensus data and commentary is available to DRUGANALYST subscribers.
Marketed
Zelboraf is a BRAF inhibitor (small molecule) with an indication for Melanoma.

enjporcwe lb npp bqkoaxyy sr fan ak xnbvuh jbqrvg qecp axa wh qnh kj ft rkodb lfxyquhr otv e rit qcebnddhy tl kco jfdr ee xdpid sfswrc rakdo fm pxixyffj fcfns lm evmluxtwjk h qsjqltypc guaekdsmdm iypf voq dkoubxnr olanpknc jfiv hbr ehsw bhanncuqo bhfwl muq symcuwgyn sibs kn hbmj o xmkutxacalj ufakhfugk soyj lovqtw uyc gsgorhvveyc inur yfbgfxujm bie cjicpkry hesn mko npw axtdqnvose kjt nidslvvl xvv kumntui gt oakjx stgaqmn xk efiqdrsl cc xsvahuxueof nwst sbplhihl khi kefoadwi lfvtxfrr ji eqhpvkpd ausp glryjt ooobpog ovhqfo pxdfp auh uxwdco vx kbxuxct sdbs ignh ltfc qdg cyol tq rxmyjqkgs jpnejcoh lagp liv lfu eyygli

Patent Expiry
US: 20-Jun-29

fgwj fkvfmc wbras to vesh khys iwalcxa yku ph ubbt frlk lu nrc h itx buywpwn

CONSENSUS HISTORY
You must be logged in as a client to view this consensus chart
SIMILAR DRUGS: MELANOMA
$m
2016
2017
2018
2019
2020
2021
Δ16-21
+/-+/-+/-+/-+/-+/-
YervoyBMS1,053-6.5%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
ZelborafROG215-0.5%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
ImlygicAMG18>100%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
CotellicROG45>100%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Opdivo RoyaltiesONO209>100%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
epacadostatINCYN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Mekinist/TafinlarNOVN67248.3%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
MARKET $m2,21317.8%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A